StockData

Aspira Women's Health Inc. (AWHL) company profile

AWHLOTCIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 1/30
$0.22−0.01 (-2.61%)

Close on Oct 19, 2026Market cap $9.91MP/E –Yield –

About Aspira Women's Health

In Vitro & In Vivo Diagnostic Substances, SIC 2835

Aspira Women’s Health Inc. develops and commercializes diagnostic tests focused on women's gynecologic health. The company specializes in the risk assessment and differential diagnosis of gynecologic diseases, primarily ovarian cancer and conditions such as endometriosis and pelvic masses. Its commercial offerings and pipeline include diagnostic solutions such as Ova1, Overa, Ova1Plus, OvaWatch, ENDOinform, and OVAinform, as well as the Aspira Synergy platform. The company provides laboratory-developed tests through its dedicated laboratory facility, Aspira Labs.

The company operates within the United States, providing diagnostic products and clinical laboratory services to healthcare providers and patients. Aspira Women's Health maintains operating facilities in Austin, Texas, and Shelton, Connecticut. Its corporate headquarters and principal executive offices are situated in Austin, Texas.

Summary of the business section of Aspira Women's Health's latest annual report, written by StockData.

Company profile

Company

Legal name
Aspira Women's Health Inc.
Headquarters
Austin, TX
Address
12117 Bee Caves Road Building Three, Suite 100 78738
Phone
(512) 519-0400
Employees
36, Dec 31, 2025
Industry
In Vitro & In Vivo Diagnostic Substances
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
BDO USA, P.C, Boston, Massachusetts

Stock & identifiers

Ticker
AWHL
Former tickers
AWH until Aug 13, 2025; VRML until Aug 14, 2020
Exchange
OTC
IPO date
Oct 2, 2000
Shares outstanding
47M, Aug 12, 2026
Public float
$4.67M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-15 reverse, May 12, 2023; 1-for-10 reverse, Mar 4, 2008
SEC CIK
926617
CUSIP
04537Y208
ISIN
US04537Y2081
FIGI
BBG000BTYP37
Share class FIGI
BBG001SSBCM2
EIN
33-0595156

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
John StrahleyChief Financial Officer–
Brian HungerfordChief Financial Officer–
Michael William BuhleChief Executive Officer–
James C. CrawfordVice President of Finance–
Sandra MilliganInterim CEO13,644
Jeffrey k. cohenDirector457,028
John D. FraserDirector854,162
Cynthia D. HundorfeanDirector–
Ellen BeausangDirector6,458
Winfred ParnellDirector71,209
Jane Pine WoodDirector–
Ellen O'Connor VosDirector73,989
John Phillip RagardDirector134,734
Stefanie L. CavanaughDirector78,726
Jannie Prestridge HerchukDirector82,502
Celeste Rachelle FralickDirector55,665

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Michael Buhle
$419.93K$575.88K$141.05K$1–
FY2025
Nicole Sandford
$0$0$141.05K$1–
FY2025
Sandra Milligan
$80.51K$79.71K$141.05K$1–
FY2024
Michael Buhle
$0$0$173.55K$1–
FY2024
Nicole Sandford
$1.24M$834.85K$173.55K$1–
FY2024
Sandra Milligan
$358.43K$281.76K$173.55K$1–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsOtherTotalvs. prior year
Michael Buhle
Chief Executive Officer
$374.52K$45.41K–$419.93K–
Brian Hungerford
Chief Financial Officer
–$38.30K$102.75K$141.05K–
Sandra Milligan, M.D., J.D.
Former President, Interim Chief Executive Officer
$80.51K––$80.51K-78%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 36 full-time employees and two part-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Apr 1, 2026Late filingNotification of late filing
May 15, 2025Late filingNotification of late filing
Apr 16, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 14, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 31, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 14, 2024Late filingNotification of late filing
Oct 18, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 5, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 14, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 2, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 2, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 10, 2020Name changeName changed from VERMILLION, INC. to Aspira Women's Health Inc.
Mar 31, 2020Late filingNotification of late filing
Jan 31, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 6, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 26, 2018Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 7, 2013Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 10, 2012Auditor changeChange in certifying accountant (8-K Item 4.01)
Jul 6, 2010ListingRegistration of securities on an exchange (Form 8-A)
May 17, 2010Late filingNotification of late filing
Mar 31, 2010Late filingNotification of late filing
Jan 25, 2010BankruptcyBankruptcy or receivership (8-K Item 1.03)
Jan 12, 2010BankruptcyBankruptcy or receivership (8-K Item 1.03)
Apr 1, 2009Late filingNotification of late filing
Mar 31, 2009BankruptcyBankruptcy or receivership (8-K Item 1.03)
Dec 5, 2008DelistingNotice of delisting from exchange (Form 25)
Sep 26, 2008Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 31, 2008Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 27, 2008Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 17, 2007Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)

See a number that looks wrong?